---
title: Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique
nct_id: NCT03766672
overall_status: COMPLETED
sponsor: University Hospital Center of Martinique
study_type: OBSERVATIONAL
primary_condition: Endometrial Neoplasms
countries: Martinique
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03766672.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03766672"
ct_last_update_post_date: 2024-08-21
last_seen_at: "2026-05-12T06:26:30.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique

**NCT ID:** [NCT03766672](https://clinicaltrials.gov/study/NCT03766672)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** University Hospital Center of Martinique
- **Collaborators:** Martinique Cancer Registry
- **Conditions:** Endometrial Neoplasms
- **Start Date:** 2019-11-22
- **Completion Date:** 2024-07-22
- **CT.gov Last Update:** 2024-08-21

## Brief Summary

In Martinique, about 33 new cases are diagnosed per year, with a high incidence rate of type 2 endometrial carcinoma which has a poor prognosis with few therapeutic options. Although targeted therapies are used in many types of cancer, they are still possible a minority of patients. In current practice, endometrial cancers do not benefit these therapies. Characterization of the molecular mechanisms involved in the genesis of type 2 endometrial carcinoma could help to identify biomarkers predictive of a response to targeted therapies. We propose to identify the genetic profile of type 2 endometrial carcinomas in Martinique.

## Detailed Description

Type 2 endometrial carcinomas are often diagnosed at advanced stages, with an high risk of metastatic recurrence and death even when diagnosed at early stages. They also have few therapeutic options. The Characterize the mutations responsible of cancer development has led to develope "precision medicine" that targets "actionable genes" by a drug. This concept of actionable mutation refers to a change in the DNA molecule that can predict the response to a drug defined as targeted therapy. Although targeted therapies are used in many types of cancer, they still target a minority of patients. Some tumor sites still do not benefit from these treatments. Specifically, type 2 endometrial cancers that have poor prognosis with few therapeutic options. The characterization of molecular mechanisms, by Next Generation Sequencing (NGS), involved in the carcinogenesis of endometrial cancers, particularly type 2 cancers, should allow the identification of predictive biomarkers for response to certain targeted therapies.

## Eligibility

- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Major subject living in Martinique with the following characteristics :

  * Patients with type 2 endometrial cancer, with anatomopathological confirmation
  * Affiliate or beneficiary of french social security.
  * Free, informed with a written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any research required by the research).

Exclusion Criteria:

* Type 1 adenocarcinoma
* Patients not affiliated to french social security
* Refusal to participate.
```

## Arms

- **Intervention Arm** — Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .

## Interventions

- **Intervention Arm** (DIAGNOSTIC_TEST) — The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.

## Primary Outcomes

- **Number of biomarkers identified by Next Generation Sequencing involved in type 2 endometrial tumors in Martinique** _(time frame: 24 Months)_ — Characterization of potentially operable mutations in type 2 endometrial tumors from DNA sample withdraw at inclusion and during follow visit

## Locations (1)

- Chu Martinique, Fort-de-France, Martinique

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu martinique|fort-de-france||martinique` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03766672.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03766672*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*